Aethlon Medical (AEMD, Financial) has announced its participation in the upcoming Keystone Symposium, focusing on Long COVID and other post-acute infection syndromes. The company's abstract has been accepted for a poster presentation, scheduled to be held from August 10-13, 2025, at the Eldorado Hotel & Spa in Santa Fe, NM, United States.
The symposium will address Long COVID, a condition characterized by ongoing symptoms that persist following an acute SARS-CoV-2 infection. These can include fatigue, post-exertional malaise, breathing difficulties, chest pain, and cognitive challenges such as "brain fog," which may linger for weeks or even months after the initial infection.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Aethlon Medical Inc (AEMD, Financial) is $3.88 with a high estimate of $7.00 and a low estimate of $0.75. The average target implies an upside of 46.82% from the current price of $2.64. More detailed estimate data can be found on the Aethlon Medical Inc (AEMD) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Aethlon Medical Inc's (AEMD, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Aethlon Medical Inc (AEMD, Financial) in one year is $100.60, suggesting a upside of 3711.76% from the current price of $2.6392. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Aethlon Medical Inc (AEMD) Summary page.
